What is MRD?
Minimal residual disease (MRD) is one of the strongest predictors of outcomes in multiple myeloma, CLL, and B-ALL
MRD refers to the number of cancer cells that can stay in the body during and after treatment. These cells are at such low levels that they do not cause any physical signs or symptoms. But that doesn’t mean the cancer is totally gone.1
Therefore, your doctor needs very precise options, like clonoSEQ®, to help measure MRD and assess your response to treatment over time.1-5
MRD: What You
Need to Know
Today, new treatments are helping patients like you live longer than ever before. If you are a candidate for clonoSEQ, reliable and precise MRD testing with clonoSEQ can:
- Tell you how much cancer is detected when the cancer is present at a very low level
- Help your doctor measure your response to treatment
- Help you and your doctor understand your prognosis now or at any point in your disease journey1
This knowledge can support shared decision-making about your future treatment plans.
When your MRD status shifts, you may find that the course of your blood cancer journey changes as well.
Learn more about MRD
This page is intended for a US-based audience.
clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
- clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020. https://clonoseq.com/technical-summary
- Pulsipher M, et al. Blood. 2015;125(22):3501-3508.
- Wood B, et al. Blood. 2018;131(12):1350-1359.
- Perrot A, et al. Blood. 2018;132(23):2456-2464.
- Thompson P, et al. Blood. 2019;134(22):1951-1959.
- Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
- Friend B, et al. Pediatr Blood Cancer. 2020;67(2):e28079.
- Al-Sawaf O, et al. J Clin Oncol. 2021;JCO2101181.